Prometic receives C$11.4 million purchase order from Multinational client
15 April 2015
ProMetic Life Sciences Inc. recently announced that it has received an C$11.4 million purchase order for the supply of affinity resin from an existing client, a global leader in the biotherapeutics industry.
The company which comprises three areas of business focus: therapeutic plasma proteins, small-molecule drug discovery and bioseparations, is an international business based in Canada, America and the UK with a manufacturing plant in the Isle of Man. The Isle of Man plant manufactures adsorbent materials used for the purification of protein pharmaceuticals.
This is the second purchase order resulting from the license and long-term supply agreement previously announced on July 8, 2013. The affinity resin will be manufactured by ProMetic at its Isle of Man facility and supplied to the client throughout the second half of 2015 and the first half of 2016. ProMetic’s client will use the resin for large-scale purification of a therapeutic protein product manufactured in large quantities.
“We are pleased to see the value and market advantages provided by our state of the art affinity purification products being recognized by some of the most reputable multinationals in the industry. The magnitude of this second purchase order clearly confirms the anticipated growth in demand for these products that we expect to see going forward”, stated Dr. Steve Burton, PBL’s Chief Executive Officer.
Find out more about Prometic